Sofinnova Partners announced that Myricx Bio has agreed to be acquired by Novartis in a transaction valued at up to $1.5 billion, including $1.1 billion cash upfront and potential milestone payments. The deal, expected to close in the second half of 2026 pending customary conditions, combines Novartis’s oncology capabilities with Myricx’s first‑in‑class N‑myristoyltransferase inhibitor (NMTi) payload platform for antibody‑drug conjugates (ADCs).
Novartis‑Myricx Bio Deal Details
The acquisition brings together Novartis’s global oncology development and commercial infrastructure with Myricx Bio’s differentiated ADC technology. Myricx, a UK‑headquartered biotech spun out of Imperial College London and the Francis Crick Institute, has built a platform around next‑generation NMTi payloads designed to improve the therapeutic index of ADCs. Its two lead assets target the B7‑H3 and HER2 antigens and are intended for a broad range of solid‑tumor indications.
Financial terms disclosed include up to $1.5 billion total consideration, of which $1.1 billion will be paid in cash at signing. The remaining amount is tied to milestone payments, the specifics of which were not disclosed. The transaction marks Sofinnova Partners’ seventh exit in three years and reflects the firm’s continued involvement from seed investment in 2019 through to this exit.
Market and Funding Context
Myricx Bio’s development has been supported by a series of high‑profile investors. After seed funding from Sofinnova Partners and Brandon Capital in 2019, the company raised a £90 million ($114 million) Series A round in mid‑2024. The round was led by Novo Holdings and Abingworth and included participation from the British Business Bank, Cancer Research Horizons, Eli Lilly, Brandon Capital, and Sofinnova Partners. Leadership changes include the appointment of Mohit Rawat as CEO in 2025, under whose direction the company advanced pre‑clinical development toward the acquisition.
Sofinnova Partners highlighted its role in steering Myricx’s strategic pivot from small‑molecule programs to the ADC payload platform, a shift it describes as “transformative” for the company’s technology. Quotes from Sofinnova’s chairman Antoine Papiernik and partner Maina Bhaman emphasize the acquisition as validation of European life‑science innovation and the venture‑backed model that identified and nurtured the technology.
Relevance for Financial Institutions
The transaction underscores several points of interest for banks, investors, and other financial service providers:
- M&A Activity in Biotech: The $1.5 billion valuation reflects continued appetite among large pharmaceutical groups for acquiring niche technology platforms that can expand their oncology pipelines. Financial institutions may see increased deal flow in similar niche‑technology acquisitions.
- Venture Capital Lifecycle: Sofinnova Partners’ involvement from seed to exit illustrates a full‑cycle venture model that can generate sizable returns. Firms tracking venture‑backed exits can use this case to benchmark fund performance and assess the viability of early‑stage investments in differentiated ADC technologies.
- Regulatory and Closing Risks: The deal is subject to customary closing conditions, including regulatory approvals, with an expected close in H2 2026. Lenders and advisors will need to monitor antitrust and other regulatory reviews that commonly accompany large pharma acquisitions.
- Milestone‑Based Payments: The structure includes contingent milestone payments, a common feature in biotech deals that aligns seller incentives with post‑acquisition performance. Credit analysts may need to model these contingent liabilities when assessing the buyer’s cash flow impact.
Key Takeaways
- The acquisition values Myricx Bio at up to $1.5 billion, with $1.1 billion paid in cash upfront and additional milestone payments.
- Myricx’s platform centers on first‑in‑class NMTi payloads for ADCs, targeting B7‑H3 and HER2 across multiple solid‑tumor types.
- The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.
FinanceInsyte's Take
The Novartis‑Myricx deal highlights the premium placed on differentiated ADC technology and the role of European venture capital in scaling such assets to acquisition. While the cash component is clear, the size and timing of milestone payments remain uncertain, and regulatory review timelines could affect the final close date. Financial executives should watch for how the integration of Myricx’s platform influences Novartis’s pipeline valuation and whether similar niche biotech assets attract comparable valuations in upcoming M&A cycles.
Source: Businesswire
